Novo Nordisk A/S's Brief Value Run Seems Over
Novo Nordisk has a fortress franchise in diabetes, but how much should investors pay for a fortress these days?
Will Teva Pharmaceutical Industries LTD Shares Wilt Under the Federal Microscope?
Teva is facing a federal investigation, at what could prove to be just the wrong time.
3 Key Takeaways From Teva's Fourth Quarter
Let’s discuss 3 key takeaways from Teva’s fourth quarter earnings, and if rising competition in MS treatments from Novartis, Biogen, and Sanofi will eventually doom the company.